---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-23-000016"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:49:41.827032+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track

## Summary
- Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.
- Cash, equivalents, marketable securities and restricted cash $204.9M at Sept 30, 2023, expected runway into 2026.
- SPY001 anti-α4β7 IND expected H1 2024; healthy volunteer interim data year-end 2024.
- SPY002 anti-TL1A IND expected H2 2024; picomolar affinity for monomer/trimer cited.
- Stockholder vote Nov 21 to authorize preferred-to-common conversion; sold pegzilarginase to Immedica for $15M upfront plus milestones.

## SEC filing metadata
- accession: 0001636282-23-000016
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/0001636282-23-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/agle-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-23-000016
- JSON: https://secwatch.observer/filing/0001636282-23-000016.json
- Plain text: https://secwatch.observer/filing/0001636282-23-000016.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On November 9, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/0001636282-23-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.